Skip to main content
SpringerLink
Log in

Management of Calcium Channel Antagonist Overdose

  • Practical Drug Safety
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Calcium channel antagonists are used primarily for the treatment of hypertension and tachyarrhythmias. Overdose of calcium channel antagonists can be lethal. Calcium channel antagonists act at the L-type calcium channels primarily in cardiac and vascular smooth muscle preventing calcium influx into cells with resultant decreases in vascular tone and cardiac inotropy and chronotropy. The L-type calcium channel is a complex structure and is thus affected by a large number of structurally diverse antagonists. In the setting of overdose, patients may experience vasodilatation and bradycardia leading to a shock state. Patients may also be hyperglycaemic and acidotic due to the blockade of L-type calcium channels in the pancreatic islet cells that affect insulin secretion. Aggressive therapy is warranted in the setting of toxicity. Gut decontamination with charcoal, or whole bowel irrigation or multiple-dose charcoal in the setting of extended-release products is indicated. Specific antidotes include calcium salts, glucagon and insulin. Calcium salts may be given in bolus doses or may be employed as a continuous infusion. Care should be exercised to avoid the administration of calcium in the setting of concomitant digoxin toxicity. Insulin administration has been used effectively to increase cardiac inotropy and survival. The likely mechanism involves a shift to carbohydrate metabolism in the setting of decreased availability of carbohydrates due to decreased insulin secretion secondary to blockade of calcium channels in pancreatic islet cells. Glucose should be administered as well to maintain euglycaemia. Supportive care including the use of phosphodiesterase inhibitors, adrenergic agents, cardiac pacing, balloon pump or extracorporeal bypass is frequently indicated if antidotal therapy is not effective. Careful evaluation of asymptomatic patients, including and electrocardiogram and a period of observation, is indicated. Patients ingesting a nonsustained-release product should be observed in a monitored setting for 12 hours, while those who ingest a sustained-release preparation should be observed for no less than 24 hours. Charcoal should be given to the asymptomatic patient with a history of calcium channel antagonist overdose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2

Similar content being viewed by others

References

  1. Hille B. Ionic channels of excitable membranes. Sunderland (MA): Sinauer, 1992

    Google Scholar 

  2. Perez-Reyes E, Cribbs LL, Daud A, et al. Molecular characteristics of neuronal low voltage activated t-type calcium channel. Nature 1998; 391: 896–900

    Article  PubMed  CAS  Google Scholar 

  3. Plummer MR, Logothetis DE, Hess P. Elementary properties and pharmacological sensitivities of calcium channels in mammalian peripheral neurons. Neuron 1989; 2: 1453–63

    Article  PubMed  CAS  Google Scholar 

  4. Catterall W. Molecular properties of sodium and calcium channels. J Bioenerg Biomembr 1996; 28: 219–30

    Article  PubMed  CAS  Google Scholar 

  5. Mitterdorfer J, Grabner M, Kraus RL, et al. Molecular basis of drug interaction with L-type Ca2+ channels. J Bioenerg Biomembr 1998; 30(4): 319–34

    Article  PubMed  CAS  Google Scholar 

  6. Clusin WT, Anderson ME. Calcium channel blockers: current controversies and basic mechanisms of action. Adv Pharmacol 1999; 46: 253–96

    Article  PubMed  CAS  Google Scholar 

  7. Welling A, Ludwig A, Zimmer S, et al. Alternatively spliced IS6 segments of the alpha 1C gene determine the tissue-specific dihydropyridine sensitivity of cardiac and vascular smooth muscle L-type Ca2+ channels. Circ Res 1997; 81(4): 526–32

    Article  PubMed  CAS  Google Scholar 

  8. Braunwald E. Mechanism of action of calcium-channel-blocking agents. N Engl J Med 1982; 307(26): 1618–27

    Article  PubMed  CAS  Google Scholar 

  9. Siesjo BK. Calcium-mediated processes in neuronal degeneration. Ann N Y Acad Sci 1994; 747: 140–61

    Article  PubMed  CAS  Google Scholar 

  10. Bers DM, Perez-Reyes E. Ca channels in cardiac myocytes: structure and function in Ca influx and intracellular Ca release. Cardiovasc Res 1999; 42(2): 339–60

    Article  PubMed  CAS  Google Scholar 

  11. du Souich P, Besner JG, Clozel JP, et al. Nonlinear kinetics and pharmacologic response to mibefradil. Clin Pharmacol Ther 2000; 67(3): 249–57

    Article  PubMed  Google Scholar 

  12. Wolf BA, Eder AF, Shaw LM. Glycols. In: Shaw LM, Kwong TC, Rosano TG, Orsulak PJ, Wolf BA, Magnani BJ, editors. The clinical toxicology laboratory-contemporary practice of poisoning evaluation. 1st ed. Washington, DC: AACCPress, 2001: 197–208

    Google Scholar 

  13. Goodman and Gilman’s The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1924–2023

  14. Pearigen PD. Calcium channel blocker poisoning. In: Haddad LM, Shannon MW, Winchester JF, editors. Clinical management of poisoning and drug overdose. 3rd ed. Philadelphia:, WB Saunders, 1998: 1020–30

    Google Scholar 

  15. Somogyi A, Albrecht M, Kliems G, et al. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis. Br J Clin Pharmacol 1981; 12(1): 51–60

    Article  PubMed  CAS  Google Scholar 

  16. Woodcock BG, Rietbrock N. Verapamil bioavailability and dosage in liver disease. Br J Clin Pharmacol 1982; 13(2): 240–1

    Article  PubMed  CAS  Google Scholar 

  17. McAllister Jr RG, Hamann SR, Blouin RA. Pharmacokinetics of calcium-entry blockers. Am J Cardiol 1985; 55(3): 30B–40B

    Article  PubMed  CAS  Google Scholar 

  18. Godfraind T, Salomone S, Dessy C, et al. Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J Cardiovasc Pharmacol 1992; 20Suppl. 5: S34–41

    PubMed  CAS  Google Scholar 

  19. Zusman RM, Higgins J, Christensen D, et al. Bepridil improves left ventricular performance in patients with angina pectoris. J Cardiovasc Pharmacol 1993; 22(3): 474–80

    Article  PubMed  CAS  Google Scholar 

  20. Hollingshead LM, Faulds D, Fitton A. Bepridil: a review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs 1992; 44(5): 835–57

    Article  PubMed  CAS  Google Scholar 

  21. Mishra SK, Hermsmeyer K. Selective inhibition of T-type Ca2+ channels by Ro 40-5967. Circ Res 1994; 75(1): 144–8

    Article  PubMed  CAS  Google Scholar 

  22. Fang LM, Osterrieder W. Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy. Eur J Pharmacol 1991; 196(2): 205–7

    Article  PubMed  CAS  Google Scholar 

  23. Osterrieder W, Holck M. In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action. J Cardiovasc Pharmacol 1989; 13(5): 754–9

    PubMed  CAS  Google Scholar 

  24. Bean BP. Classes of calcium channels in vertebrate cells. Annu Rev Physiol 1989; 51: 367–84

    Article  PubMed  CAS  Google Scholar 

  25. Tseng GN, Boyden PA. Multiple types of Ca2+ currents in single canine Purkinje cells. Circ Res 1989; 65(6): 1735–50

    Article  PubMed  CAS  Google Scholar 

  26. Sandmann S, Claas R, Cleutjens JP, et al. Calcium channel blockade limits cardiac remodelling and improves cardiac function in myocardial infarction-induced heart failure in rats. J Cardiovasc Pharmacol 2001; 37(1): 64–77

    Article  PubMed  CAS  Google Scholar 

  27. Sandmann S, Bohle RM, Dreyer T, et al. The T-type calcium channel blocker mibefradil reduced interstitial and perivascular fibrosis and improved hemodynamic parameters in myocardial infarction-induced cardiac failure in rats. Virchows Arch 2000; 436(2): 147–57

    Article  PubMed  CAS  Google Scholar 

  28. Sandmann S, Spitznagel H, Chung O, et al. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats. Cardiovasc Res 1998; 39(2): 339–50

    Article  PubMed  CAS  Google Scholar 

  29. Glasser SP. The relevance of T-type calcium antagonists: a profile of mibefradil. J Clin Pharmacol 1998; 38(8): 659–69

    PubMed  CAS  Google Scholar 

  30. Buckley CD, Aronson JK. Prolonged half-life of verapamil in a case of overdose: implications for therapy. Br J Clin Pharmacol 1995; 39(6): 680–3

    Article  PubMed  CAS  Google Scholar 

  31. Ferner RE, Odemuyiwa O, Field AB, et al. Pharmacokinetics and toxic effects of diltiazem in massive overdose. Hum Toxicol 1989; 8(6): 497–9

    Article  PubMed  CAS  Google Scholar 

  32. Ferner RE, Monkman S, Riley J, et al. Pharmacokinetics and toxic effects of nifedipine in massive overdose. Hum Exp Toxicol 1990; 9(5): 309–11

    Article  PubMed  CAS  Google Scholar 

  33. Roberts D, Honcharik N, Sitar DS, et al. Diltiazem overdose: pharmacokinetics of diltiazem and its metabolites and effect of multiple dose charcoal therapy. J Toxicol Clin Toxicol 1991; 29(1): 45–52

    Article  PubMed  CAS  Google Scholar 

  34. Spiller HA, Meyers A, Ziemba T, et al. Delayed onset of cardiac arrhythmias from sustained-release verapamil. Ann Emerg Med 1991; 20(2): 201–3

    Article  PubMed  CAS  Google Scholar 

  35. Tom PA, Morrow CT, Kelen GD. Delayed hypotension after overdose of sustained release verapamil. J Emerg Med 1994; 12(5): 621–5

    Article  PubMed  CAS  Google Scholar 

  36. Ramoska EA, Spiller HA, Winter M, et al. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. Ann Emerg Med 1993; 22(2): 196–200

    Article  PubMed  CAS  Google Scholar 

  37. Abernethy DR, Schwartz JB. Calcium-antagonist drugs. N Engl J Med 1999; 341(19): 1447–57

    Article  PubMed  CAS  Google Scholar 

  38. Price WA, Giannini AJ. Neurotoxicity caused by lithium-verapamil synergism. J Clin Pharmacol 1986; 26 (8): 717–9

    Google Scholar 

  39. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99(10): 2545–53

    Article  PubMed  CAS  Google Scholar 

  40. Salhanick SD, Wax PM. Treatment of atenolol overdose in a patient with renal failure using serial hemodialysis and hemoperfusion and associated echocardiographic findings. Vet Hum Toxicol 2000; 42(4): 224–5

    PubMed  CAS  Google Scholar 

  41. Pearigen PD, Benowitz NL. Poisoning due to calcium antagonists: experience with verapamil, diltiazem and nifedipine. Drug Saf 1991; 6(6): 408–30

    Article  PubMed  CAS  Google Scholar 

  42. Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. Am J Emerg Med 1995; 13(4): 444–50

    Article  PubMed  CAS  Google Scholar 

  43. DeRoos F. Calcium channel blockers. In: Goldfrank LG, editor. Goldfrank’s toxicologic emergencies. 7th ed. Stamford (CT): Appleton and Lange, 2002: 762–74

    Google Scholar 

  44. McGovern B, Garan H, Ruskin JN. Precipitation of cardiac arrest by verapamil in patients with Wolff-Parkinson-White syndrome. Ann Intern Med 1986; 104(6): 791–4

    PubMed  CAS  Google Scholar 

  45. Brass BJ, Winchester-Penny S, Lipper BL. Massive verapamil overdose complicated by noncardiogenic pulmonary edema. Am J Emerg Med 1996; 14(5): 459–61

    Article  PubMed  CAS  Google Scholar 

  46. Stanek EJ, Nelson CE, DeNofrio D. Amlodipine overdose. Ann Pharmacother 1997; 31(7-8): 853–6

    PubMed  CAS  Google Scholar 

  47. Buckley NA, Whyte IM, Dawson AH. Overdose with calcium channel blockers [letter; comment]. BMJ 1994; 308(6944): 1639

    Article  PubMed  CAS  Google Scholar 

  48. Gelbke HP, Schlicht HJ, Schmidt G. Fatal poisoning with verapamil. Arch Toxicol 1977; 37(2): 89–94

    Article  PubMed  CAS  Google Scholar 

  49. Herrington DM, Insley BM, Weinmann GG. Nifedipine overdose. Am J Med 1986; 81(2): 344–6

    Article  PubMed  CAS  Google Scholar 

  50. Howarth DM, Dawson AH, Smith AJ, et al. Calcium channel blocking drug overdose: an Australian series. Hum Exp Toxicol 1994; 13(3): 161–6

    Article  PubMed  CAS  Google Scholar 

  51. Leesar MA, Martyn R, Talley JD, et al. Noncardiogenic pulmonary edema complicating massive verapamil overdose. Chest 1994; 105(2): 606–7

    Article  PubMed  CAS  Google Scholar 

  52. Humbert Jr VH, Munn NJ, Hawkins RF. Noncardiogenic pulmonary edema complicating massive diltiazem overdose. Chest 1991; 99(1): 258–9

    Article  PubMed  Google Scholar 

  53. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol 1987; 10Suppl. 1: S121–31

    Article  PubMed  CAS  Google Scholar 

  54. Low RI, Takeda P, Mason DT, et al. The effects of calcium channel blocking agents on cardiovascular function. Am J Cardiol 1982; 49(3): 547–53

    Article  PubMed  CAS  Google Scholar 

  55. Green K, Cheeks L, Hull DS. Effects of calcium channel blockers on rabbit corneal endothelial function. Curr Eye Res 1994; 13(6): 401–8

    Article  PubMed  CAS  Google Scholar 

  56. Payne DK, Fuseler JW, Owens MW. Modulation of endothelial cell permeability by lung carcinoma cells: a potential mechanism of malignant pleural effusion formation. Inflammation 1994; 18(4): 407–17

    Article  PubMed  CAS  Google Scholar 

  57. Fedorak RN, Empey LR, Walker K. Verapamil alters eicosanoid synthesis and accelerates healing during experimental colitis in rats. Gastroenterology 1992; 102(4 Pt 1): 1229–35

    PubMed  CAS  Google Scholar 

  58. Simon RP. Neurogenic pulmonary edema. Neurol Clin 1993; 11(2): 309–23

    PubMed  CAS  Google Scholar 

  59. Malcolm N, Callegari P, Goldberg J, et al. Massive diltiazem overdosage: clinical and pharmacokinetic observations [letter]. Drug Intell Clin Pharm 1986; 20(11): 888

    PubMed  CAS  Google Scholar 

  60. Wells TG, Graham CJ, Moss MM, et al. Nifedipine poisoning in a child. Pediatrics 1990; 86(1): 91–4

    PubMed  CAS  Google Scholar 

  61. Horowitz BZ, Rhee KJ. Massive verapamil ingestion: a report of two cases and a review of the literature. Am J Emerg Med 1989; 7(6): 624–31

    Article  PubMed  CAS  Google Scholar 

  62. Fauville JP, Hantson P, Honore P, et al. Severe diltiazem poisoning with intestinal pseudo-obstruction: case report and toxicological data. J Toxicol Clin Toxicol 1995; 33(3): 273–7

    Article  PubMed  CAS  Google Scholar 

  63. Goglin WK, Elliott BM, Deppe SA. Nifedipine-induced hypotension and mesenteric ischemia. South Med J 1989; 82(2): 274–5

    Article  PubMed  CAS  Google Scholar 

  64. Gutierrez H, Jorgensen M. Colonic ischemia after verapamil overdose [letter]. Ann Intern Med 1996; 124(5): 535

    PubMed  CAS  Google Scholar 

  65. Sporer KA, Manning JJ. Massive ingestion of sustained-release verapamil with a concretion and bowel infarction. Ann Emerg Med 1993; 22(3): 603–5

    Article  PubMed  CAS  Google Scholar 

  66. Wax PM. Intestinal infarction due to nifedipine overdose. J Toxicol Clin Toxicol 1995; 33(6): 725–8

    Article  PubMed  CAS  Google Scholar 

  67. Devis G, Somers G, Van Obberghen E, et al. Calcium antagonists and islet function: I. inhibition of insulin release by verapamil. Diabetes 1975; 24(6): 247–51

    Article  PubMed  CAS  Google Scholar 

  68. Enyeart JJ, Price WA, Hoffman DA, et al. Profound hyperglycemia and metabolic acidosis after verapamil overdose. J Am Coll Cardiol 1983; 2(6): 1228–31

    Article  PubMed  CAS  Google Scholar 

  69. Lebrun P, Malaisse WJ, Herchuelz A. Nutrient-induced intracellular calcium movement in rat pancreatic B cell. Am J Physiol 1982; 243(3): E196–205

    PubMed  CAS  Google Scholar 

  70. Malaisse WJ. Role of calcium in insulin secretion. Isr J Med Sci 1972; 8(3): 244–51

    PubMed  CAS  Google Scholar 

  71. Yuan TH, Kerns II WP, Tomaszewski CA, et al. Insulin-glucose as adjunctive therapy for severe calcium channel antagonist poisoning. J Toxicol Clin Toxicol 1999; 37(4): 463–74

    Article  PubMed  CAS  Google Scholar 

  72. Tenenbein M, Cohen S, Sitar DS. Whole bowel irrigation as a decontamination procedure after acute drug overdose. Arch Intern Med 1987; 147(5): 905–7

    Article  PubMed  CAS  Google Scholar 

  73. Tenenbein M. Whole bowel irrigation and activated charcoal. Ann Emerg Med 1989; 18(6): 707–8

    Article  PubMed  CAS  Google Scholar 

  74. Kirshenbaum LA, Mathews SC, Sitar DS, et al. Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther 1989; 46(3): 264–71

    Article  PubMed  CAS  Google Scholar 

  75. Kucukhuseyin C, Silan C. Induction of calcium-dependent action potentials by 4-aminopyridine in potassium depolarized guinea-pig papillary muscle. J Basic Clin Physiol Pharmacol 1997; 8(1-2): 81–9

    Article  PubMed  CAS  Google Scholar 

  76. Agoston S, Maestrone E, van Hezik EJ, et al. Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J Clin Invest 1984; 73(5): 1291–6

    Article  PubMed  CAS  Google Scholar 

  77. Gay R, Algeo S, Lee R, et al. Treatment of verapamil toxicity in intact dogs. J Clin Invest 1986; 77(6): 1805–11

    Article  PubMed  CAS  Google Scholar 

  78. ter Wee PM, Kremer Hovinga TK, Uges DR, et al. 4-Aminopyridine and haemodialysis in the treatment of verapamil intoxication. Hum Toxicol 1985; 4(3): 327–9

    Article  PubMed  Google Scholar 

  79. Belson MG, Gorman SE, Sullivan K, et al. Calcium channel blocker ingestions in children. Am J Emerg Med 2000; 18(5): 581–6

    Article  PubMed  CAS  Google Scholar 

  80. Perkins CM. Serious verapamil poisoning: treatment with intravenous calcium gluconate [case report]. BMJ 1978; 2(6145): 1127

    Article  PubMed  CAS  Google Scholar 

  81. Strubelt O, Diederich KW. Experimental investigations on the antidotal treatment of nifedipine overdosage. J Toxicol Clin Toxicol 1986; 24(2): 135–49

    Article  PubMed  CAS  Google Scholar 

  82. Hariman RJ, Mangiardi LM, McAllister RG, et al. Reversal of the cardiovascular effects of verapamil by calcium and sodium: differences between electrophysiologic and hemodynamic responses. Circulation 1979; 59(4): 797–804

    Article  PubMed  CAS  Google Scholar 

  83. Crump BJ, Holt DW, Vale JA. Lack of response to intravenous calcium in severe verapamil poisoning. Lancet 1982; II(8304): 939–40

    Article  Google Scholar 

  84. MacDonald D, Alguire PC. Case report: fatal overdose with sustained-release verapamil. Am J Med Sci 1992; 303(2): 115–7

    Article  PubMed  CAS  Google Scholar 

  85. Haddad LM. Resuscitation after nifedipine overdose exclusively with intravenous calcium chloride. Am J Emerg Med 1996; 14(6): 602–3

    Article  PubMed  CAS  Google Scholar 

  86. Lam YM, Tse HF, Lau CP. Continuous calcium chloride infusion for massive nifedipine overdose. Chest 2001; 119(4): 1280–2

    Article  PubMed  CAS  Google Scholar 

  87. Kline JA, Leonova E, Raymond RM. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med 1995; 23(7): 1251–63

    Article  PubMed  CAS  Google Scholar 

  88. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001; 345(19): 1359–67

    Article  PubMed  Google Scholar 

  89. Boyer EW, Shannon M. Treatment of calcium-channel-blocker intoxication with insulin infusion. N Engl J Med 2001; 344(22): 1721–2

    Article  PubMed  CAS  Google Scholar 

  90. Levey GS, Fletcher MA, Klein I, et al. Characterization of 125I-glucagon binding in a solubilized preparation of cat myocardial adenylate cyclase: further evidence for a dissociable receptor site. J Biol Chem 1974; 249(9): 2665–73

    PubMed  CAS  Google Scholar 

  91. Mery PF, Brechler V, Pavoine C, et al. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 1990; 345(6271): 158–61

    Article  PubMed  CAS  Google Scholar 

  92. Sauvadet A, Rohn T, Pecker F, et al. Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. Circ Res 1996; 78(1): 102–9

    Article  PubMed  CAS  Google Scholar 

  93. Stone CK, May WA, Carroll R. Treatment of verapamil overdose with glucagon in dogs. Ann Emerg Med 1995; 25(3): 369–74

    Article  PubMed  CAS  Google Scholar 

  94. Stone CK, Thomas SH, Koury SI, et al. Glucagon and phenylephrine combination vs glucagon alone in experimental verapamil overdose. Acad Emerg Med 1996; 3(2): 120–5

    Article  PubMed  CAS  Google Scholar 

  95. Zaritsky AL, Horowitz M, Chernow B. Glucagon antagonism of calcium channel blocker-induced myocardial dysfunction. Crit Care Med 1988; 16(3): 246–51

    Article  PubMed  CAS  Google Scholar 

  96. Sabatier J, Pouyet T, Shelvey G, et al. Antagonistic effects of epinephrine, glucagon and methylatropine but not calcium chloride against atrio-ventricular conduction disturbances produced by high doses of diltiazem, in conscious dogs. Fundam Clin Pharmacol 1991; 5(2): 93–106

    Article  PubMed  CAS  Google Scholar 

  97. Jolly SR, Kipnis JN, Lucchesi BR. Cardiovascular depression by verapamil: reversal by glucagon and interactions with propranolol. Pharmacology 1987; 35(5): 249–55

    Article  PubMed  CAS  Google Scholar 

  98. Doyon S, Roberts JR. The use of glucagon in a case of calcium channel blocker overdose. Ann Emerg Med 1993; 22(7): 1229–33

    Article  PubMed  CAS  Google Scholar 

  99. Wolf LR, Spadafora MP, Otten EJ. Use of amrinone and glucagon in a case of calcium channel blocker overdose. Ann Emerg Med 1993; 22(7): 1225–8

    Article  PubMed  CAS  Google Scholar 

  100. Walter FG, Frye G, Mullen JT, et al. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med 1993; 22(7): 1234–7

    Article  PubMed  CAS  Google Scholar 

  101. Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. N Engl J Med 1968; 279(1): 12–7

    Article  PubMed  CAS  Google Scholar 

  102. Love JN, Sachdeva DK, Bessman ES, et al. A potential role for glucagon in the treatment of drug-induced symptomatic bradycardia. Chest 1998; 114(1): 323–6

    Article  PubMed  CAS  Google Scholar 

  103. Tuncok Y, Apaydin S, Gidener S, et al. The effects of amrinone and glucagon on verapamil-induced myocardial depression in a rat isolated heart model. Gen Pharmacol 1997; 28(5): 773–6

    Article  PubMed  CAS  Google Scholar 

  104. Alousi AA, Canter JM, Fort DJ. The beneficial effect of amrinone on acute drug-induced heart failure in the anaesthetised dog. Cardiovasc Res 1985; 19(8): 483–94

    Article  PubMed  CAS  Google Scholar 

  105. Makela VH, Kapur PA. Amrinone and verapamil-propranolol induced cardiac depression during isoflurane anesthesia in dogs. Anesthesiology 1987; 66(6): 792–7

    Article  PubMed  CAS  Google Scholar 

  106. Goenen M, Col J, Compere A, et al. Treatment of severe verapamil poisoning with combined amrinone-isoproterenol therapy. Am J Cardiol 1986; 58(11): 1142–3

    Article  PubMed  CAS  Google Scholar 

  107. Ramoska EA, Spiller HA, Myers A. Calcium channel blocker toxicity. Ann Emerg Med 1990; 19(6): 649–53

    Article  PubMed  CAS  Google Scholar 

  108. Snover SW, Bocchino V. Massive diltiazem overdose. Ann Emerg Med 1986; 15(10): 1221–4

    Article  PubMed  CAS  Google Scholar 

  109. Watling SM, Crain JL, Edwards TD, et al. Verapamil overdose: case report and review of the literature. Ann Pharmacother 1992; 26(11): 1373–8

    PubMed  CAS  Google Scholar 

  110. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993; 95(4): 431–8

    Article  PubMed  CAS  Google Scholar 

  111. Hendren WG, Schieber RS, Garrettson LK. Extracorporeal by-pass for the treatment of verapamil poisoning. Ann Emerg Med 1989; 18(9): 984–7

    Article  PubMed  CAS  Google Scholar 

  112. Ishikawa T, Imamura T, Koiwaya Y, et al. Atrioventricular dissociation and sinus arrest induced by oral diltiazem. N Engl J Med 1983; 309(18): 1124–5

    Article  PubMed  CAS  Google Scholar 

  113. Frierson J, Bailly D, Shultz T, et al. Refractory cardiogenic shock and complete heart block after unsuspected verapamil-SR and atenolol overdose. Clin Cardiol 1991; 14(11): 933–5

    Article  PubMed  CAS  Google Scholar 

  114. Orr GM, Bodansky HJ, Dymond DS, et al. Fatal verapamil overdose. Lancet 1982; II(8309): 1218–9

    Article  Google Scholar 

  115. Holzer M, Sterz F, Schoerkhuber W, et al. Successful resuscitation of a verapamil-intoxicated patient with percutaneous cardiopulmonary bypass. Crit Care Med 1999; 27(12): 2818–23

    Article  PubMed  CAS  Google Scholar 

  116. Schiffl H, Ziupa J, Schollmeyer P. Clinical features and management of nifedipine overdosage in a patient with renal insufficiency. J Toxicol Clin Toxicol 1984; 22(4): 387–95

    Article  PubMed  CAS  Google Scholar 

  117. Rosansky SJ. Verapamil toxicity: treatment with hemoperfusion. Ann Intern Med 1991; 114(4): 340–1

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors wish to acknowledge the Division of Emergency Medicine and Program in Toxicology at the Children’s Hospital, Boston for administrative and financial support in the preparation of this manuscript. The authors wish to report that there are no potential conflicts of interest that affected the content of this manuscript in any way.

The authors would like to thank Edward W. Boyer, MD, PhD for input and assistance with this manuscript.

Author information

Authors and Affiliations

  1. Children’s Hospital, 300 Longwood Avenue, Boston, Massachusetts, MA 02115, USA

    Steven D. Salhanick & Michael W. Shannon

Authors
  1. Steven D. Salhanick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael W. Shannon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven D. Salhanick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salhanick, S.D., Shannon, M.W. Management of Calcium Channel Antagonist Overdose. Drug-Safety 26, 65–79 (2003). https://doi.org/10.2165/00002018-200326020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200326020-00001

Keywords

Search

Navigation